Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.

Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, Dawson R, Whitelaw A, Hoelscher M, Sharma S, Pai M, Warren R, Dheda K.

Am J Respir Crit Care Med. 2011 Jul 1;184(1):132-40. doi: 10.1164/rccm.201101-0056OC. Epub 2011 Apr 14.

PMID:
21493734
2.

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N.

Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593. doi: 10.1002/14651858.CD009593.pub3. Review.

3.

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009593. doi: 10.1002/14651858.CD009593.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(1):CD009593.

4.

Systematic review: Comparison of Xpert MTB/RIF, LAMP and SAT methods for the diagnosis of pulmonary tuberculosis.

Yan L, Xiao H, Zhang Q.

Tuberculosis (Edinb). 2016 Jan;96:75-86. doi: 10.1016/j.tube.2015.11.005. Epub 2015 Nov 30. Review.

PMID:
26786658
5.

Molecular Diagnosis of TB in the HIV Positive Population.

Vittor AY, Garland JM, Gilman RH.

Ann Glob Health. 2014 Nov-Dec;80(6):476-85. doi: 10.1016/j.aogh.2015.01.001. Review.

6.

Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review.

Maynard-Smith L, Larke N, Peters JA, Lawn SD.

BMC Infect Dis. 2014 Dec 31;14:709. doi: 10.1186/s12879-014-0709-7. Review.

7.

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults.

Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, Steingart KR.

Cochrane Database Syst Rev. 2016 May 10;(5):CD011420. doi: 10.1002/14651858.CD011420.pub2. Review.

8.

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 Apr;13(4):349-61. doi: 10.1016/S1473-3099(13)70008-2. Epub 2013 Mar 24. Review.

9.

Diagnostic Performance of Xpert MTB/RIF in Tuberculous Pleural Effusion: Systematic Review and Meta-analysis.

Sehgal IS, Dhooria S, Aggarwal AN, Behera D, Agarwal R.

J Clin Microbiol. 2016 Apr;54(4):1133-6. doi: 10.1128/JCM.03205-15. Epub 2016 Jan 27. Review.

10.

Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis.

Drobniewski F, Cooke M, Jordan J, Casali N, Mugwagwa T, Broda A, Townsend C, Sivaramakrishnan A, Green N, Jit M, Lipman M, Lord J, White PJ, Abubakar I.

Health Technol Assess. 2015 May;19(34):1-188, vii-viii. doi: 10.3310/hta19340. Review.

11.

Diagnosis of opportunistic infections: HIV co-infections - tuberculosis.

Scott L, da Silva P, Boehme CC, Stevens W, Gilpin CM.

Curr Opin HIV AIDS. 2017 Mar;12(2):129-138. doi: 10.1097/COH.0000000000000345. Review.

PMID:
28059955
12.

A model of tuberculosis screening for pregnant women in resource-limited settings using Xpert MTB/RIF.

Turnbull ER, Kancheya NG, Harris JB, Topp SM, Henostroza G, Reid SE.

J Pregnancy. 2012;2012:565049. doi: 10.1155/2012/565049. Epub 2011 Oct 5. Review.

13.

Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis.

Arentz M, Sorensen B, Horne DJ, Walson JL.

PLoS One. 2013 Oct 3;8(10):e76533. doi: 10.1371/journal.pone.0076533. eCollection 2013. Review.

14.

Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.

Lawn SD, Nicol MP.

Future Microbiol. 2011 Sep;6(9):1067-82. doi: 10.2217/fmb.11.84. Review. Erratum in: Future Microbiol. 2012 Aug;7(8):1024.

15.

Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control.

Stevens WS, Scott L, Noble L, Gous N, Dheda K.

Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TBTB2-0040-2016. Review.

PMID:
28155817
16.

Tuberculosis and HIV co-infection in children.

Venturini E, Turkova A, Chiappini E, Galli L, de Martino M, Thorne C.

BMC Infect Dis. 2014;14 Suppl 1:S5. doi: 10.1186/1471-2334-14-S1-S5. Epub 2014 Jan 8. Review.

17.

Xpert® MTB/RIF: Usefulness for the diagnosis of tuberculosis and resistance to rifampicin.

Vergara Gómez A, González-Martín J, García-Basteiro AL.

Med Clin (Barc). 2017 Jul 21. pii: S0025-7753(17)30476-1. doi: 10.1016/j.medcli.2017.06.007. [Epub ahead of print] Review. English, Spanish.

PMID:
28739268
18.

The development, evaluation and performance of molecular diagnostics for detection of Mycobacterium tuberculosis.

Bates M, Zumla A.

Expert Rev Mol Diagn. 2016;16(3):307-22. doi: 10.1586/14737159.2016.1139457. Epub 2016 Feb 17. Review.

PMID:
26735769
19.

Exploring tuberculosis by molecular tests on DNA isolated from smear microscopy slides.

Rakotosamimanana N, Rabodoarivelo MS, Palomino JC, Martin A, Razanamparany VR.

Int J Infect Dis. 2017 Mar;56:248-252. doi: 10.1016/j.ijid.2016.12.005. Epub 2016 Dec 12. Review.

20.

Drug-resistant tuberculous meningitis.

Garg RK, Jain A, Malhotra HS, Agrawal A, Garg R.

Expert Rev Anti Infect Ther. 2013 Jun;11(6):605-21. doi: 10.1586/eri.13.39. Review.

PMID:
23750732

Supplemental Content

Support Center